{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-275406","form_type":"8-K","ticker":"MCRB","cik":"0001609809","company_name":"Seres Therapeutics, Inc.","filed_at":"2022-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.394558+00:00","generated_at":"2026-06-22T14:05:00.376343+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Seres reports Q3 2022 net loss $60M; SER-109 BLA accepted for Priority Review with PDUFA April 26, 2023","bullets":["Net loss of $60.0M in Q3 2022 vs net income of $68.2M in Q3 2021; R&D expenses $43.1M.","FDA accepted SER-109 BLA for Priority Review; PDUFA target action date April 26, 2023.","ECOSPOR IV open-label study: 91.3% of patients achieved sustained clinical response at 8 weeks.","Cash, cash equivalents and marketable securities $233.0M as of Sept 30, 2022.","SER-155 cohort 1 enrollment complete; DSMB safety review by year end; initial data early 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-275406","json":"https://secwatch.observer/filing/0001193125-22-275406.json","markdown":"https://secwatch.observer/filing/0001193125-22-275406.md","text":"https://secwatch.observer/filing/0001193125-22-275406.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1609809/000119312522275406/0001193125-22-275406-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1609809/000119312522275406/d377816d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T14:05:00.376343+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"500ac7fe54a1e175c1a570bb038eaef75dd05198","claim":"Seres Therapeutics, Inc. reported financial results for third quarter 2022.","evidence_excerpt":"Seres Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2022 and provided operational updates.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312522275406/0001193125-22-275406-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}